Reuters logo
BRIEF-Colucid Pharmaceuticals announces additional analyses of Lasmiditan'S onset of action data
October 5, 2016 / 3:01 PM / a year ago

BRIEF-Colucid Pharmaceuticals announces additional analyses of Lasmiditan'S onset of action data

Oct 5 (Reuters) - Colucid Pharmaceuticals :

* Colucid pharmaceuticals announces additional analyses of Lasmiditan’s onset of action data from samurai and supporting non-clinical data

* Lasmiditan showed no vasoconstrictive activity in both in vivo and in vitro models, even at supratherapeutic doses

* Colucid Pharmaceuticals Inc says Lasmiditan crosses blood brain barrier (bbb) as early as 30 minutes after dosing in vivo

* Lasmiditan was well tolerated with no significant difference in cardiovascular adverse events in patients dosed with Lasmiditan versus placebo Source text for Eikon:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below